But a 2024 study found negligible risk to breastfeeding babies, and the tested samples of breast milk didnt have semaglutide in significant amounts
Real-world results typically fall short of trial outcomes
However, this was predominantly driven by one trial, DECLARE TIMI 58, which included healthier cohorts than other cardiovascular outcome trials (CVOT) involving SGLT-2 inhibitors [103], and this benefit of asthma risk reduction was neutralized when DECLARE TIMI 58 was excluded from the analysis [105]
Aneta Sokal-Dembowska, Ewelina Polak-Szczybyo, Kacper Helma, Patrycja Musz, Maciej Setlik, Weronika Fic, Dawid Wachowiak, Sara Jarmakiewicz-Czaja Current Issues in Molecular Biology .2025
Researchers found that people who took semaglutide lost, on average, 3.6% of their body weight after three months
FDA-approved chronic weight-management medications such as Wegovy and Zepbound are intended to be used alongside reduced-calorie eating and increased physical activity